Cart
sales@molnova.com
Siaresinolic acid 28-O-beta-D-glucopyranosyl ester
CAS No. 155653-86-4
Siaresinolic acid 28-O-beta-D-glucopyranosyl ester( —— )
Catalog No. M32148 CAS No. 155653-86-4
Siaresinolic acid 28-O-β-D-glucopyranosyl ester is a natural product for research related to life sciences.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 371 | In Stock |
|
| 10MG | 513 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSiaresinolic acid 28-O-beta-D-glucopyranosyl ester
-
NoteResearch use only, not for human use.
-
Brief DescriptionSiaresinolic acid 28-O-β-D-glucopyranosyl ester is a natural product for research related to life sciences.
-
DescriptionSiaresinolic acid 28-O-β-D-glucopyranosyl ester is a natural product for research related to life sciences.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number155653-86-4
-
Formula Weight634.9
-
Molecular FormulaC36H58O9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Dihydroevocarpine
Dihydroevocarpine shows potent anti-Helicobacter pylori activity with the minimum inhibitory concentration (MIC) value of 10-20 microg/ml. Dihydroevocarpine is a moderate modulator of p-glycoprotein (p-gp) activity; it shows more potent inhibitory effects against MAO-B compared to MAO-A.
-
Plathymenin
Plathymenin is a natural product isolated from Spatholobus suberectus.
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
